| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
AJP - Renal Physiology, Vol 259, Issue 2 312-F317, Copyright © 1990 by American Physiological Society
ARTICLES |
P. G. Cavero, W. L. Miller, D. M. Heublein, K. B. Margulies and J. C. Burnett Jr
Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905.
Studies were performed in anesthetized dogs to determine plasma endothelin (ET) concentrations in the presence and absence of experimental congestive heart failure (CHF) produced by rapid ventricular pacing for 8 days. These studies were also designed to determine the effect of exogenous low-dose ET upon integrated cardiorenal and endocrine function in the presence and absence of CHF. In these studies, plasma ET was significantly elevated in CHF (3.25 +/- 0.39 pg/ml) compared with normal (1.03 +/- 0.21 pg/ml) or sham-operated (1.08 +/- 0.27 pg/ml) groups. Compared with the control group, which was characterized by a significant cardiorenal vasoconstrictor response to low-dose ET, a significant attenuation of the vasoconstrictor and antinatriuretic actions of ET was observed in the CHF group. Despite these differential responses, exogenous ET suppressed plasma renin activity (PRA) and activated aldosterone in both control and CHF groups. Thus these studies demonstrate for the first time that experimental CHF is characterized by elevated plasma ET in association with an attenuated cardiorenal response to exogenous ET. In contrast, low-dose ET inhibited PRC and activated aldosterone in the presence and absence of experimental CHF.
This article has been cited by other articles:
|
|
 |
|
  K. Tadano, J. Suzuki, K. Hanada, M. Nakao, R. Nakao, S. Uehara, H. Ohta, T. Miyauchi, and M. Nishikibe Pathophysiological Roles of Endogenous Endothelin-1 in Dogs with Chronic Heart Failure Produced by Rapid Right Ventricular Pacing J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 729 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Suzuki and T. Miyauchi A novel pharmacological action of ET-1 to prevent the cytotoxicity of doxorubicin in cardiomyocytes Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2001; 280(5): R1399 - R1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Onishi, M. Ohno, W. C. Little, and C.-P. Cheng Endogenous Endothelin-1 Depresses Left Ventricular Systolic and Diastolic Performance in Congestive Heart Failure J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1214 - 1222. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Oie, R. Bjonerheim, H. K. Grogaard, H. Kongshaug, O. A. Smiseth, and H. Attramadal ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats Am J Physiol Heart Circ Physiol, September 1, 1998; 275(3): H868 - H877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Kelso, J. P. Spiers, B. J. McDermott, C. N. Scholfield, and B. Silke Receptor-Mediated Effects of Endothelin on the L-Type Ca++ Current in Ventricular Cardiomyocytes J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 662 - 669. [Abstract] [Full Text]
|
|
|
|
 |
|
 Z. Abassi, K. Gurbanov, I. Rubinstein, O. S. Better, A. Hoffman, and J. Winaver Regulation of intrarenal blood flow in experimental heart failure: role of endothelin and nitric oxide Am J Physiol Renal Physiol, April 1, 1998; 274(4): F766 - F774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Haug, W. Koenig, M. Hoeher, M. Kochs, V. Hombach, A. Gruenert, and H. Osterhues Direct enzyme immunometric measurement of plasma big endothelin-1 concentrations and correlation with indicators of left ventricular function Clin. Chem., February 1, 1998; 44(2): 239 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Delp, C. Duan, J. P. Mattson, and T. I. Musch Changes in skeletal muscle biochemistry and histology relative to fiber type in rats with heart failure J Appl Physiol, October 1, 1997; 83(4): 1291 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Oie, L. E. Vinge, T. Tonnessen, H. K. Grogaard, H. Kjekshus, G. Christensen, O. A. Smiseth, and H. Attramadal Transient, isopeptide-specific induction of myocardial endothelin-1 mRNA in congestive heart failure in rats Am J Physiol Heart Circ Physiol, October 1, 1997; 273(4): H1727 - H1736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mulder, V. Richard, G. Derumeaux, M. Hogie, J. P. Henry, F. Lallemand, P. Compagnon, B. Mace, E. Comoy, B. Letac, et al. Role of Endogenous Endothelin in Chronic Heart Failure : Effect of Long-term Treatment With an Endothelin Antagonist on Survival, Hemodynamics, and Cardiac Remodeling Circulation, September 16, 1997; 96(6): 1976 - 1982. [Abstract] [Full Text]
|
|
|
|
|
|
C. R. Cannan, J. C. Burnett Jr, and A. Lerman Enhanced Coronary Vasoconstriction to Endothelin-BReceptor Activation in Experimental Congestive Heart Failure Circulation, February 15, 1996; 93(4): 646 - 651. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. L. Zhang, H. S. Mackenzie, K. Totsune, J. L. Troy, and B. M. Brenner Renal Effects of High-Dose Natriuretic Peptide Receptor Blockade in Rats With Congestive Heart Failure Circ. Res., December 1, 1995; 77(6): 1240 - 1245. [Abstract] [Full Text]
|
|
|
|
|
|
T. Hiramatsu, J. Forbess, T. Miura, S. J. Roth, M. A. Cioffi MAT, and J. E. Mayer Jr Effects of Endothelin-1 and Endothelin-A Receptor Antagonist on Recovery After Hypothermic Cardioplegic Ischemia in Neonatal Lamb Hearts Circulation, November 1, 1995; 92(9): 400 - 404. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
